Tyra biosciences reports fourth quarter and full year 2023 financial results and highlights

- advanced surf301 phase 1 oncology study; initial phase 1 results to be reported in 2h 2024 - - tyra-300 phase 2 ach ind submission on track for 2h 2024 - - initiated surf201 phase 1 study and dosed first patient with tyra-200 - - strengthened balance sheet with approximately $200 million pipe in q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million - carlsbad, calif. , march 19, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the fourth quarter and full year ended december 31, 2023 and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking